Olympus Partners-backed PAI Pharma completed the acquisition of Nivagen.

Olympus Partners-backed PAI Pharma, an American developer, manufacturer and distributor of generic oral liquids, completed the acquisition of Nivagen, a specialty pharmaceuticals company. Financial terms were not disclosed. "Olympus is proud to continue supporting PAI as it expands into sterile injectables. We believe the combination of PAI's leadership in RTU oral liquids and Nivagen's injectable platform creates a unique business that is well-positioned to serve hospitals and healthcare providers with critical, high-quality medicines," Griffin Barstis, Olympus Partners Partner.